***Table S1****. Measured outcomes during intensive care stay and hospital mortality in all the patients and in patients with and without CAPA.*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **OUTCOME** | **All population****(n=579)** | **No CAPA****(n=483)** | **CAPA****(n=96)** | **p value** |
| **ICU mortality (n, %)** | 157 (27,1%) | 109 (22,6%) | 48 (50%) | **<0.001** |
| **90-day mortality (n, %)** | 182 (31,5%) | 130 (27%) | 52 (54,2%) | **<0.001** |
| **ICU length of stay (days; median, IQR)** | 8 (4-18) | 7 (4-14) | 19 (8-39) | **<0.001** |
| **Hospital length of stay (days; median, IQR)** | 23 (15-37) | 22(14-35) | 31 (20-54) | **<0.001** |
| **Mechanical ventilation-free days at day 60 (days; median, IQR)** | 51 (0-57) | 53 (0-58) | 0 (0-35) | **<0.001** |
| **Time to CAPA occurrence (days; median, IQR)** | 5,5 (1,0-12,0) |  | 5,5 (1,0-12,0) |  |
| **Secondary bacterial infection (n, %)** | 200 (34, 5%) | 139 (28.8%) | 61 (63.5%) | **<0.001** |
| **Bacteremia (n, %)** | 85 (14,7%) | 61 (12.7%) | 24 (25%) | **0.002** |
| **Pneumonia (n, %)** | 162 (28%) | 113 (23.4%) | 49 (51%) | **<0.001** |
| **Viral reactivations (n, %)** | 181 (58,8%) | 128 (53,8%) | 53 (75,7%) | **0.001** |
| **CMV reactivation (n, %)** | 117 (20,6) | 77 (16,3) | 40 (41,7) | **<0,001** |
| **Peak CMV-DNA load (copies/ml; median, IQR)** | 671 (194-1741) | 441 (155-1374) | 1077 (499-2649) | **0,015** |
| **Time to CMV reactivation (days; median, IQR)** | 14(4-24) | 13 (3-23) | 18 (7-27) | **0,154** |